JP2019514998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514998A5 JP2019514998A5 JP2018559221A JP2018559221A JP2019514998A5 JP 2019514998 A5 JP2019514998 A5 JP 2019514998A5 JP 2018559221 A JP2018559221 A JP 2018559221A JP 2018559221 A JP2018559221 A JP 2018559221A JP 2019514998 A5 JP2019514998 A5 JP 2019514998A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sucrose
- pharmaceutical composition
- binding fragment
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 229930006000 Sucrose Natural products 0.000 claims 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 11
- 239000005720 sucrose Substances 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 5
- 229920000053 polysorbate 80 Polymers 0.000 claims 5
- 229940068968 polysorbate 80 Drugs 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608323.0A GB201608323D0 (en) | 2016-05-12 | 2016-05-12 | Pharmaceutical compositions |
| GB1608323.0 | 2016-05-12 | ||
| PCT/EP2017/061261 WO2017194646A1 (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514998A JP2019514998A (ja) | 2019-06-06 |
| JP2019514998A5 true JP2019514998A5 (enExample) | 2020-05-21 |
| JP7126454B2 JP7126454B2 (ja) | 2022-08-26 |
Family
ID=56320265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559221A Active JP7126454B2 (ja) | 2016-05-12 | 2017-05-11 | 医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11407835B2 (enExample) |
| EP (1) | EP3454899B1 (enExample) |
| JP (1) | JP7126454B2 (enExample) |
| KR (1) | KR102436694B1 (enExample) |
| CN (1) | CN109069643A (enExample) |
| AR (1) | AR108449A1 (enExample) |
| AU (1) | AU2017264553A1 (enExample) |
| BR (1) | BR112018072264A2 (enExample) |
| CA (1) | CA3022124A1 (enExample) |
| CL (1) | CL2018003178A1 (enExample) |
| CO (1) | CO2018011733A2 (enExample) |
| EA (1) | EA201892446A1 (enExample) |
| ES (1) | ES2977545T3 (enExample) |
| GB (1) | GB201608323D0 (enExample) |
| IL (1) | IL262654A (enExample) |
| MX (1) | MX2018013215A (enExample) |
| SG (1) | SG11201809229VA (enExample) |
| WO (1) | WO2017194646A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2910584A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| CA3094934A1 (en) * | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| CN115484931A (zh) * | 2020-03-11 | 2022-12-16 | 西莱克塔生物科技公司 | 与合成纳米载体相关的方法和组合物 |
| EP4173637A4 (en) * | 2020-06-29 | 2024-08-07 | Hanall Biopharma Co., Ltd. | FORMULATION FOR ANTI-FCRN ANTIBODIES |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
| WO2023099607A1 (en) | 2021-12-01 | 2023-06-08 | UCB Biopharma SRL | Formulations comprising fab-peg |
| CN119233815A (zh) * | 2022-05-20 | 2024-12-31 | 株式会社大赛璐 | 液态医药组合物 |
| KR20250018382A (ko) | 2022-05-30 | 2025-02-05 | 한올바이오파마주식회사 | 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편 |
| CN115708810A (zh) * | 2022-11-03 | 2023-02-24 | 浙江新码生物医药有限公司 | 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
| CN120882751A (zh) * | 2023-03-08 | 2025-10-31 | 依牧诺万科学有限公司 | 含聚山梨酯赋形剂的高浓度蛋白质制剂及其制备方法 |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| BRPI0711608B8 (pt) * | 2006-05-12 | 2021-05-25 | Bharat Biotech Int Ltd | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| WO2010148337A1 (en) * | 2009-06-18 | 2010-12-23 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US8788028B2 (en) | 2010-07-28 | 2014-07-22 | Medtronic, Inc. | Parasympathetic stimulation to enhance tachyarrhythmia detection |
| EP2648750B1 (en) | 2010-12-10 | 2017-01-25 | Novartis AG | Antibody formulation |
| US9220776B2 (en) * | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| CA3204402A1 (en) * | 2012-03-26 | 2013-10-03 | Sanofi | Stable anti-cxcr5 igg4 antibody formulations |
| US9592289B2 (en) * | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| WO2014093206A1 (en) | 2012-12-13 | 2014-06-19 | Merck Sharp & Dohme Corp. | Lyophilized spherical pellets of anti-il-23 antibodies |
| TW201542226A (zh) * | 2014-02-12 | 2015-11-16 | Sanofi Sa | 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物 |
| AU2015332151A1 (en) | 2014-10-18 | 2017-04-27 | Pfizer Inc. | Anti-IL-7R antibody compositions |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
-
2016
- 2016-05-12 GB GBGB1608323.0A patent/GB201608323D0/en not_active Ceased
-
2017
- 2017-05-11 MX MX2018013215A patent/MX2018013215A/es unknown
- 2017-05-11 AR ARP170101248A patent/AR108449A1/es not_active Application Discontinuation
- 2017-05-11 KR KR1020187036132A patent/KR102436694B1/ko active Active
- 2017-05-11 CN CN201780028404.3A patent/CN109069643A/zh active Pending
- 2017-05-11 CA CA3022124A patent/CA3022124A1/en active Pending
- 2017-05-11 SG SG11201809229VA patent/SG11201809229VA/en unknown
- 2017-05-11 EP EP17725544.5A patent/EP3454899B1/en active Active
- 2017-05-11 EA EA201892446A patent/EA201892446A1/ru unknown
- 2017-05-11 AU AU2017264553A patent/AU2017264553A1/en not_active Abandoned
- 2017-05-11 ES ES17725544T patent/ES2977545T3/es active Active
- 2017-05-11 WO PCT/EP2017/061261 patent/WO2017194646A1/en not_active Ceased
- 2017-05-11 JP JP2018559221A patent/JP7126454B2/ja active Active
- 2017-05-11 US US16/300,522 patent/US11407835B2/en active Active
- 2017-05-11 BR BR112018072264-2A patent/BR112018072264A2/pt not_active IP Right Cessation
-
2018
- 2018-10-28 IL IL262654A patent/IL262654A/en unknown
- 2018-10-30 CO CONC2018/0011733A patent/CO2018011733A2/es unknown
- 2018-11-08 CL CL2018003178A patent/CL2018003178A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514998A5 (enExample) | ||
| RU2019100887A (ru) | Композиции антитела и белка | |
| JP2016534052A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| EA201892446A1 (ru) | Фармацевтическая композиция | |
| JP2014514346A5 (enExample) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| FI3408295T3 (fi) | Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus | |
| JP2016515511A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2015120605A (ru) | Стабильная композиция белка иммуноглобулина с двойными вариабельными доменами | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| JP2020536109A5 (enExample) | ||
| JP2015526440A5 (enExample) | ||
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| CN114616249A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| HRP20190672T1 (hr) | Konjugirane formulacije anti-egfr protutijelo-lijek | |
| RU2014140137A (ru) | Лекарственный препарат антитела к бета-амилоиду | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| PE20171512A1 (es) | Anticuerpos anti-fap | |
| JP2017113019A5 (enExample) | ||
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| RU2011142184A (ru) | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами |